Top executive says AI likely to affect healthcare more than any other area of life.
Kimberly Powell, Nvidia’s vice president of healthcare, stated that generative artificial intelligence (AI) has sparked a healthcare revolution and will significantly impact pharmaceutical research, patient diagnostics, and post-operative treatment.
Powell emphasized that while it’s still early days, healthcare is likely to be more influenced by AI than any other area of life.
AI is already being utilized in developing and testing new drugs, significantly reducing the time and cost associated with the process, which can take up to 15 years and $2 billion.
Powell highlighted AI’s potential in drug discovery, citing its ability to intelligently search vast chemical spaces and improve researchers’ understanding of how new compounds interact with the body, potentially reducing the high failure rate of drugs in clinical trials.
